{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,7]],"date-time":"2024-07-07T16:31:25Z","timestamp":1720369885344},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Current treatment of high-grade osteosarcoma consists of preoperative chemotherapy, typically using some combination of doxorubicin, cisplatin, ifosfamide, and\/or high-dose methotrexate followed by surgical resection. In this report, we present a case of a 21-year-old woman with high-grade osteosarcoma of the chest wall who received 5 times the planned dose of doxorubin and 4 times the planned dose of ifosfamide. She survived this chemotherapy overdose after administration of dimethyl sulfoxide and phenobarbital. Despite the administration of 5 times the proposed dose of doxorubicin, the patient survived without cardiotoxicity, and later delivered a normal baby. Although there are many studies evaluating treatment for chemotherapy regimen-related toxicity, sparse data exist with respect to chemotherapy overdose and the appropriate course of action. This case further confirms the lower cardiotoxicity of continuous intravenous infusion of doxorubicin and provides support for the use of dimethyl sulfoxide in the prevention of toxicity in chemotherapy overdose.<\/jats:p>","DOI":"10.1097\/mph.0000000000001264","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T03:25:31Z","timestamp":1532489131000},"page":"e94-e96","source":"Crossref","is-referenced-by-count":4,"title":["Long-term Outcome After Doxorubicin and Ifosfamide Overdose in a Patient With Osteosarcoma and BARD1 Mutation"],"prefix":"10.1097","volume":"41","author":[{"given":"Malvi","family":"Savani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith M.","family":"Skubitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1200\/JCO.2012.43.8598","article-title":"Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis","volume":"31","author":"Collins","year":"2013","journal-title":"J Clin Oncol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.jacc.2015.04.013","article-title":"Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study","volume":"65","author":"Armstrong","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2010.33.4730","article-title":"High risk of symptomatic cardiac events in childhood cancer survivors","volume":"30","author":"van der Pal","year":"2012","journal-title":"J Clin Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"133","DOI":"10.7326\/0003-4819-96-2-133","article-title":"Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion","volume":"96","author":"Legha","year":"1982","journal-title":"Ann Intern Med"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"710","DOI":"10.7326\/0003-4819-91-5-710","article-title":"Risk factors for doxorubicin-induced congestive heart failure","volume":"91","author":"Von Hoff","year":"1979","journal-title":"Ann Intern Med"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/0277-5379(89)90135-1","article-title":"Doxorubicin: effect of different schedules on toxicity and anti-tumor efficacy","volume":"25","author":"Bielack","year":"1989","journal-title":"Eur J Cancer Clin Oncol"},{"key":"R7-20230918","first-page":"97","article-title":"A phase I study of ambulatory continuos infusion chemotherapy with cyclophosphamide, doxorubicin, and dacarbazine (caCAD) for soft tissue sarcomas","volume":"2","author":"Hamdan","year":"1992","journal-title":"J Infus Chemother"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1200\/JCO.1983.1.1.24","article-title":"Constant infusion schedule for adriamycin: a phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system","volume":"1","author":"Lokich","year":"1983","journal-title":"J Clin Oncol"},{"key":"R9-20230918","first-page":"971","article-title":"Continuous venous infusion of doxorubicin in advanced sarcomas","volume":"71","author":"Samuels","year":"1987","journal-title":"Cancer Treat Rep"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/1097-0142(19900215)65:4<870::AID-CNCR2820650407>3.0.CO;2-D","article-title":"Reduced cardiotoxicity of doxorubicin by a 6-hour infusion regimen. A prospective randomized evaluation","volume":"65","author":"Shapira","year":"1990","journal-title":"Cancer"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/83.13.926","article-title":"Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study","volume":"83","author":"Zalupski","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"R12-20230918","first-page":"1416","article-title":"Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function","volume":"37","author":"Benjamin","year":"1977","journal-title":"Cancer Res"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Invest"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","article-title":"Doxorubicin pathways: pharmacodynamics and adverse effects","volume":"21","author":"Thorn","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1734-1140(10)70328-5","article-title":"Fullerenol C60(OH)24 prevents doxorubicin-induced acute cardiotoxicity in rats","volume":"62","author":"Torres","year":"2010","journal-title":"Pharmacol Rep"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1634\/theoncologist.12-11-1351","article-title":"The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas","volume":"12","author":"Tascilar","year":"2007","journal-title":"Oncologist"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1172\/JCI109626","article-title":"Generation of hydroxyl radical by enzymes, chemicals, and human phagocytes in vitro. Detection with the anti-inflammatory agent, dimethyl sulfoxide","volume":"64","author":"Repine","year":"1979","journal-title":"J Clin Invest"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1136\/jmg.2004.020669","article-title":"Mutation screening of the BARD1 gene: evidence for involvement of the Cys557Ser allele in hereditary susceptibility to breast cancer","volume":"41","author":"Karppinen","year":"2004","journal-title":"J Med Genet"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"10424","DOI":"10.1038\/srep10424","article-title":"Analysis of large mutations in BARD1 in patients with breast and\/or ovarian cancer: the Polish population as an example","volume":"5","author":"Klonowska","year":"2015","journal-title":"Sci Rep"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature24060","article-title":"BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing","volume":"550","author":"Zhao","year":"2017","journal-title":"Nature"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ygyno.2011.12.415","article-title":"Hereditary ovarian cancer: beyond the usual suspects","volume":"124","author":"Pennington","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"18032","DOI":"10.1073\/pnas.1115052108","article-title":"Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing","volume":"108","author":"Walsh","year":"2011","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00043426-201903000-00025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:53:53Z","timestamp":1695012833000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00043426-201903000-00025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001264","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]}}}